x
NEW AND NOW APPROVED
Download the results of the MARIPOSA study
Please see full Prescribing Information for RYBREVANT®.
Please see full Prescribing Information for LAZCLUZE™.
This product information is intended for US healthcare professionals only.
Third-party trademarks used herein are trademarks of their respective owners.
© Janssen Biotech, Inc. 2024 08/24 cp-206563v7
Mechanism of Action
The first and only approved EGFR-MET bispecific antibody with immune cell–directing activity1
RYBREVANT® targets multiple disease mechanisms in patients with EGFR exon 20 insertion mutations1,2:
BLOCKS
EGFR and MET activity
DEGRADES
EGFR and MET
ACTIVATES*†
immune cell responses
See how RYBREVANT® works
Watch this video about the MOA of RYBREVANT®, engineered to take on EGFR exon 20 insertion mutations1
*Trogocytosis is a process in which one cell, in this case macrophages, physically extracts and ingests cellular material of another cell.2
†Antibody-dependent cellular cytotoxicity (ADCC) involves the release of cytotoxic granules that cause tumor cell death.2,3
Mechanism of Action Video
Combining the ability of RYBREVANT® to engage immune cells with chemotherapy-mediated cell death could have complementary antitumor activity4,5
Explore
It's time for a new first-line treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; NSCLC, non-small cell lung cancer.
Register for Updates
Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.
References
1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. Cho BC, Simi A, Sabari J, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89-97.
3. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing in lung cancer cells. MAbs. 2017; 9(1):114-126.
4. Zhou C, Tang K-J, Cho BC, et al; PAPILLON Investigators. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039-2051.
5. Nagasaka M, Goto K, Gomez J, et al. Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Poster presented at IASLC World Conference on Lung Cancer. 8-14, 2021.